| Recruiting | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) NCT07202052 | Monash University | Phase 2 / Phase 3 |
| Recruiting | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Thr NCT06667687 | AbbVie | Phase 1 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Recruiting | Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for NCT06520163 | The Affiliated People's Hospital of Ningbo University | Phase 3 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) NCT06285422 | Sana Biotechnology | Phase 1 |
| Unknown | F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma NCT06206902 | Shanghai Simnova Biotechnology Co.,Ltd. | Phase 1 |
| Recruiting | A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies NCT06066203 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL NCT06014073 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Living Conditions After Non-Hodgkin's Lymphoma in France NCT05583318 | Centre Hospitalier Universitaire Dijon | — |
| Recruiting | A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL NCT05806099 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Cord Blood Transplant in Adults With Blood Cancers NCT05884333 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies NCT05618028 | AbbVie | Phase 1 |
| Recruiting | Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL NCT05554939 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT05623982 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Chidamide Bridging for CAR-T Therapy NCT05370547 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chim NCT05349266 | Zhejiang University | Phase 1 |
| Recruiting | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases NCT04662294 | Zhejiang University | EARLY_Phase 1 |
| Terminated | 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma NCT05096234 | Stanford University | Phase 1 |
| Unknown | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study NCT05191225 | Laida Cuevas Palomares | Phase 4 |
| Unknown | Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma NCT05206071 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Unknown | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies NCT04796675 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematologic NCT04532203 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymp NCT04586478 | Juventas Cell Therapy Ltd. | Phase 2 |
| Unknown | A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non NCT04666168 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Unknown | Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma NCT04447547 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Terminated | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymph NCT04156828 | University of Washington | Phase 1 |
| Unknown | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignanc NCT04226989 | He Huang | EARLY_Phase 1 |
| Terminated | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or NCT04155840 | University of Washington | Phase 2 |
| Recruiting | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies NCT03765177 | Ottawa Hospital Research Institute | Phase 1 / Phase 2 |
| Unknown | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) NCT04028440 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Active Not Recruiting | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial NCT03844048 | AbbVie | Phase 3 |
| Active Not Recruiting | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma NCT03789240 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma NCT04002947 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma NCT03974243 | Chipscreen Biosciences, Ltd. | Phase 1 / Phase 2 |
| Completed | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies NCT03955783 | Sanjay Mohan | Phase 1 |
| Terminated | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas NCT03893682 | Aptose Biosciences Inc. | Phase 1 |
| Unknown | Vaccination With Flt3L, Radiation, and Poly-ICLC NCT03789097 | Icahn School of Medicine at Mount Sinai | Phase 1 / Phase 2 |
| Terminated | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies NCT03797261 | AbbVie | Phase 1 |
| Unknown | Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With NCT04497688 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | N/A |
| Completed | MB-CART20.1 Lymphoma NCT03664635 | Miltenyi Biomedicine GmbH | Phase 1 / Phase 2 |
| Completed | A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients NCT04152148 | Bio-Thera Solutions | Phase 1 |
| Completed | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) NCT03527147 | Acerta Pharma BV | Phase 1 |
| Active Not Recruiting | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas NCT03198026 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed o NCT03236857 | AbbVie | Phase 1 |
| Completed | Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin NCT03317899 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Bl NCT02961881 | Amgen | Phase 1 |
| Enrolling By Invitation | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing NCT03226704 | National Cancer Institute (NCI) | — |
| Completed | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas NCT03188965 | Bayer | Phase 1 |
| Terminated | Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma NCT03074825 | Chipscreen Biosciences, Ltd. | Phase 1 |
| Unknown | Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma NCT03456466 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Admi NCT03075696 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer NCT03027284 | Eli Lilly and Company | Phase 1 |
| Completed | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT NCT03018223 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome NCT02848274 | Stanford University | — |
| Completed | A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Cond NCT02919670 | Dana-Farber Cancer Institute | N/A |
| Unknown | A Study of Mitoxantrone Hydrochloride Liposome Infusion NCT02856685 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Completed | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular L NCT02611323 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma o NCT02722733 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 3 |
| Terminated | A Study of PLX51107 in Advanced Malignancies NCT02683395 | Plexxikon | Phase 1 |
| Completed | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation NCT02719821 | University of Wisconsin, Madison | N/A |
| Terminated | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) NCT02624986 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 NCT02507336 | University of Miami | Phase 2 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Completed | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplant NCT02356159 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymp NCT02453087 | Hoffmann-La Roche | Phase 1 |
| Withdrawn | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) NCT02408042 | Western Regional Medical Center | Phase 1 / Phase 2 |
| Terminated | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgki NCT01609816 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Terminated | GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conv NCT02360111 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies NCT02315118 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Completed | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies NCT02223052 | Celgene | Phase 1 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord NCT01930162 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas NCT02259556 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Li NCT02199288 | Hoffmann-La Roche | — |
| Completed | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma NCT02059239 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Active Not Recruiting | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) NCT02050347 | Baylor College of Medicine | Phase 1 |
| Withdrawn | A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 NCT01969682 | AbbVie | Phase 1 |
| Completed | A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma NCT02078102 | Sherif S. Farag | Phase 2 |
| Unknown | Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation NCT02087657 | University of Kansas Medical Center | N/A |
| Completed | Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma NCT02697552 | HUYABIO International, LLC. | Phase 1 |
| Completed | An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma NCT01969695 | AbbVie | Phase 1 |
| Completed | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies NCT02006485 | TG Therapeutics, Inc. | Phase 1 |
| Completed | PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy NCT01910025 | Polaris Group | Phase 2 |
| Completed | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 NCT01969669 | AbbVie | Phase 1 |
| Completed | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma NCT01980654 | Pharmacyclics LLC. | Phase 2 |
| Unknown | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Imm NCT02007811 | University of Erlangen-Nürnberg Medical School | Phase 1 / Phase 2 |
| Completed | Meloxicam vs Placebo for Mobilization NCT02003625 | Massachusetts General Hospital | Phase 2 |
| Completed | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Mal NCT01854567 | Mesoblast, Ltd. | Phase 3 |
| Completed | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant NCT01904175 | Duke University | — |
| Completed | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor NCT01696461 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NH NCT01767714 | Sanofi | Phase 3 |
| Active Not Recruiting | High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor ( NCT01840566 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers NCT01597219 | University College, London | Phase 2 |
| Withdrawn | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folo NCT01789723 | Acrotech Biopharma Inc. | Phase 1 |
| Terminated | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL NCT01728207 | Gilead Sciences | Phase 1 |
| Completed | Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma NCT01768338 | Michael John Robertson | Phase 1 |
| Recruiting | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE NCT01555892 | Baylor College of Medicine | Phase 1 |
| Completed | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies NCT01767766 | TG Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based NCT01746849 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma NCT01755975 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Terminated | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Mal NCT01745913 | Weill Medical College of Cornell University | Phase 2 |
| Completed | An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular NCT01684865 | Hoffmann-La Roche | — |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or NCT01458288 | GPCR Therapeutics, Inc. | Phase 2 |
| Terminated | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant NCT01699581 | Greg Monohan | Phase 2 |
| Completed | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab NCT01592370 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Terminated | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL NCT01585688 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | A Study of LY3023414 in Participants With Advanced Cancer NCT01655225 | Eli Lilly and Company | Phase 1 |
| Completed | Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disord NCT01610180 | Fondazione Progetto Ematologia | Phase 2 |
| Completed | A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) NCT01594229 | AbbVie | Phase 1 |
| Terminated | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies NCT01643603 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Terminated | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Withdrawn | Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT NCT01598558 | Sanjiv Sam Gambhir | N/A |
| Completed | A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Re NCT01461928 | Hoffmann-La Roche | Phase 3 |
| Completed | Reduced Intensity Double Umbilical Cord Blood Transplantation NCT01408563 | Massachusetts General Hospital | Phase 2 |
| Completed | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide NCT01458366 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Terminated | Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-gra NCT01549886 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Completed | IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma NCT01491841 | Anne Beaven, MD | Phase 1 |
| Withdrawn | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy NCT01452334 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) NCT01316146 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. NCT01878890 | Institut Bergonié | Phase 1 |
| Completed | Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Ne NCT01763398 | Yonsei University | — |
| Completed | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cycloph NCT01342289 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed NCT01332968 | Hoffmann-La Roche | Phase 3 |
| Completed | FLT PET: A Pilot Study in Lymphoma Patients NCT04028804 | The Hospital for Sick Children | — |
| Completed | Imaging Based Dosimetry for Individualized Internal Emitter Therapy NCT01988272 | University of Michigan | — |
| Active Not Recruiting | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma NCT01192464 | Baylor College of Medicine | Phase 1 |
| Completed | AMG 319 Lymphoid Malignancy FIH NCT01300026 | Amgen | Phase 1 |
| Completed | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases NCT01336712 | Northside Hospital, Inc. | Phase 2 |
| Completed | Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation NCT01339572 | University of Florida | Phase 2 |
| Terminated | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps NCT01350258 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Terminated | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanc NCT01296555 | Genentech, Inc. | Phase 1 |
| Completed | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies NCT01321346 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Completed | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma NCT01180049 | Pfizer | Phase 4 |
| Completed | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts Wit NCT01200758 | Hoffmann-La Roche | Phase 3 |
| Completed | A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma NCT01929265 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Active Not Recruiting | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study NCT01269593 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Terminated | Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma NCT01316523 | University of California, Davis | Phase 2 |
| Completed | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancie NCT01221857 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refra NCT01203020 | West Virginia University | Phase 2 |
| Terminated | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Ritu NCT01200589 | Novartis Pharmaceuticals | Phase 3 |
| Completed | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) NCT01402687 | Dana-Farber Cancer Institute | — |
| Completed | Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's L NCT01164475 | Genzyme, a Sanofi Company | Phase 4 |
| Completed | Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) NCT01205503 | Mara Chambers | Phase 2 |
| Terminated | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL NCT01187810 | South Plains Oncology Consortium | Phase 1 |
| Completed | High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lym NCT01182415 | Massachusetts General Hospital | Phase 2 |
| Completed | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer NCT01149668 | Pharmacyclics LLC. | Phase 1 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Completed | Mozobil for Autologous Stem Cell Mobilization NCT01164345 | Sheba Medical Center | Phase 2 |
| Withdrawn | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL NCT01101581 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation NCT01068301 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) NCT01059630 | Genentech, Inc. | Phase 3 |
| Terminated | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combina NCT01021423 | Celgene | Phase 3 |
| Completed | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT01118845 | SymBio Pharmaceuticals | Phase 2 |
| Completed | Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma NCT01060384 | University of Nebraska | Phase 1 / Phase 2 |
| Terminated | Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) NCT01090973 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Pati NCT01073163 | Cephalon | Phase 3 |
| Terminated | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogen NCT00984165 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLC NCT01063439 | Inje University | Phase 2 |
| Terminated | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lym NCT01032148 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium NCT00896454 | Amgen | Phase 2 |
| Completed | A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment NCT01007292 | Astellas Pharma Inc | Phase 2 |
| Completed | Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (N NCT03792815 | Soonchunhyang University Hospital | Phase 2 |
| Completed | Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma NCT00969462 | Meir Medical Center | Phase 4 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Completed | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers NCT00788684 | AbbVie | Phase 1 |
| Completed | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refr NCT00944905 | Bristol-Myers Squibb | Phase 1 |
| Completed | R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial NCT01133158 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Terminated | Study of Repeat Intranodal Injections of Ad-ISF35 NCT00942409 | Januario Castro, M.D. | Phase 2 |
| Unknown | Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients NCT00931229 | National Health Research Institutes, Taiwan | N/A |
| Completed | Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era NCT00902434 | Oncology Specialists, S.C. | — |
| Completed | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatme NCT00877006 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B NCT00926757 | Taipei Veterans General Hospital, Taiwan | Phase 4 |
| Active Not Recruiting | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas NCT00877214 | Jurgen Barth | Phase 3 |
| Active Not Recruiting | Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT NCT00840853 | Baylor College of Medicine | Phase 1 |
| Recruiting | GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and O NCT02872987 | Goethe University | — |
| Completed | Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymp NCT00864942 | Georgetown University | Phase 1 |
| Completed | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodg NCT00825149 | Hoffmann-La Roche | Phase 1 |
| Terminated | Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT NCT01144754 | Stanford University | — |
| Terminated | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma NCT00809341 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene NCT00710892 | Baylor College of Medicine | Phase 1 |
| Completed | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Ho NCT00794638 | SymBio Pharmaceuticals | Phase 1 |
| Terminated | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allo NCT00909948 | Massachusetts General Hospital | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function NCT00652626 | Celgene | Phase 1 |
| Terminated | Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma NCT00775957 | University of Oklahoma | — |
| Completed | CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma NCT00659425 | MedImmune LLC | Phase 1 |
| Completed | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT NCT00709592 | Virginia Commonwealth University | Phase 2 |
| Terminated | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade NCT00714259 | University of Alabama at Birmingham | Phase 2 / Phase 3 |
| Completed | Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-In NCT00712582 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Fol NCT00719472 | Genentech, Inc. | Phase 3 |
| Completed | Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies NCT00691210 | Columbia University | Phase 1 |
| Completed | Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas NCT00685997 | UMC Utrecht | — |
| Terminated | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma NCT00788606 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed NCT00517049 | Genentech, Inc. | Phase 2 |
| Completed | A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's L NCT00622258 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T NCT00648037 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prio NCT00670592 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat NCT00791011 | Amgen | Phase 1 |
| Completed | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant NCT00597714 | David Rizzieri, MD | Phase 2 |
| Completed | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma NCT00576758 | Hoffmann-La Roche | Phase 2 |
| Terminated | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transp NCT00674427 | University of Pennsylvania | Phase 1 |
| Completed | Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell NCT00646750 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Completed | Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma NCT00612183 | SymBio Pharmaceuticals | Phase 2 |
| Completed | A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B NCT00556699 | Genentech, Inc. | Phase 1 |
| Completed | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients W NCT00665314 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00558727 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Completed | Investigation of the Cylex® ImmuKnow® Assay NCT00569842 | Indiana University School of Medicine | — |
| Completed | Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma NCT00547534 | University of Rochester | Phase 2 |
| Completed | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Mye NCT00469729 | Gamida Cell -Teva Joint Venture Ltd. | Phase 2 / Phase 3 |
| Completed | Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00550615 | University of Nebraska | Phase 1 / Phase 2 |
| Completed | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) NCT00608907 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma NCT00533728 | Biotec Pharmacon ASA | Phase 1 |
| Withdrawn | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL NCT00577161 | CTI BioPharma | Phase 3 |
| Terminated | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar NCT00475332 | University of Florida | Phase 2 |
| Completed | Positron Emission Tomography(PET) in Lymphoma Assessment NCT00887718 | University Health Network, Toronto | N/A |
| Unknown | Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease NCT00515892 | Cambridge Antibody Technology | Phase 1 |
| Terminated | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM NCT00499239 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following NCT00510315 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials NCT00487513 | Dana-Farber Cancer Institute | — |
| Completed | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies NCT00504972 | Weill Medical College of Cornell University | Phase 1 |
| Completed | Zevalin-beam for Aggressive Lymphoma NCT00491491 | Sheba Medical Center | Phase 3 |
| Completed | Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL NCT00504751 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Re NCT00477945 | Indiana University School of Medicine | Phase 1 |
| Terminated | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide NCT01300793 | University of California, San Francisco | Phase 1 |
| Terminated | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Ho NCT00452127 | Genentech, Inc. | Phase 1 / Phase 2 |
| Terminated | Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment Wi NCT00510471 | Genitope Corporation | Phase 2 |
| Completed | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Rad NCT00777114 | Weill Medical College of Cornell University | Phase 1 |
| Unknown | Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chem NCT00463463 | Soroka University Medical Center | Phase 3 |
| Unknown | Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With R NCT00438581 | McGill University | Phase 2 |
| Completed | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancie NCT00697671 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | IMPACT Non Hodgkins Lymphoma (NHL) Study NCT00903812 | Amgen | — |
| Completed | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous T NCT00434629 | University of Pennsylvania | Phase 1 |
| Completed | Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy NCT00606216 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma NCT00797810 | University of Bologna | Phase 4 |
| Completed | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers NCT00421213 | Alaunos Therapeutics | Phase 2 |
| Completed | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCT00406809 | AbbVie (prior sponsor, Abbott) | Phase 1 / Phase 2 |
| Completed | A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma NCT00389051 | SymBio Pharmaceuticals | Phase 1 |
| Completed | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma NCT00430352 | Hoffmann-La Roche | Phase 4 |
| Completed | Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance NCT00581646 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL NCT00369707 | Northwestern University | Phase 2 |
| Completed | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematolog NCT00460694 | Singapore General Hospital | Phase 1 / Phase 2 |
| Terminated | Ph II CHOP+Velcade in Mediastinal LBCL NCT00361621 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients Wit NCT01018758 | Gruppo Italiano Studio Linfomi | Phase 2 |
| Completed | Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma NCT00354926 | Applied Molecular Evolution | Phase 1 |
| Completed | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymp NCT00336583 | Asan Medical Center | Phase 2 |
| Completed | Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Plac NCT00741325 | Genzyme, a Sanofi Company | — |
| Terminated | Gemcitabine for Marginal Zone Lymphoma NCT00337259 | Asan Medical Center | Phase 2 |
| Terminated | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, No NCT00400764 | Genentech, Inc. | Phase 1 / Phase 2 |
| Completed | An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) NCT02782845 | Hoffmann-La Roche | Phase 4 |
| Completed | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cel NCT00571493 | University of Nebraska | Phase 1 / Phase 2 |
| Completed | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma NCT00343564 | Cytokinetics | Phase 1 / Phase 2 |
| Completed | PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation NCT00352703 | Swedish Orphan Biovitrum | Phase 4 |
| Completed | A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients W NCT00597519 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma NCT00312845 | Millennium Pharmaceuticals, Inc. | Phase 3 |
| Completed | Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL) NCT00842114 | Fundación Leucemia y Linfoma, Spain | Phase 2 |
| Completed | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 NCT00818480 | Astellas Pharma Inc | Phase 2 |
| Completed | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HC NCT00285259 | Astellas Pharma Inc | Phase 2 |
| Terminated | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies NCT00276159 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies NCT00273936 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Completed | Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss NCT00352846 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL NCT01527422 | Fernando Cabanillas | Phase 1 / Phase 2 |
| Terminated | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell L NCT00274651 | Valerio Therapeutics | Phase 2 |
| Completed | Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies NCT00256191 | Cortice Biosciences, Inc. | Phase 1 |
| Completed | Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma NCT00336843 | Asan Medical Center | Phase 2 |
| Terminated | Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's NCT00250861 | US Oncology Research | Phase 2 |
| Completed | Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who NCT00139841 | Cephalon | Phase 3 |
| Completed | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With NCT00283439 | Amgen | Phase 1 / Phase 2 |
| Completed | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Mal NCT00150462 | Amgen | Phase 1 |
| Completed | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus NCT00133367 | Massachusetts General Hospital | Phase 2 |
| Completed | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases NCT00309842 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonf NCT01153971 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) NCT02723071 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas NCT00183976 | University of Southern California | Phase 2 |
| Completed | Unrelated Donor Stem Cell Transplantation NCT01364363 | Scripps Health | N/A |
| Unknown | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leuk NCT00109356 | Novacea | Phase 1 / Phase 2 |
| Terminated | Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patie NCT00120198 | Geriatric Oncology Consortium | Phase 2 |
| Terminated | Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance NCT00582166 | University of Wisconsin, Madison | Phase 2 |
| Completed | Behavioral Intervention For BMT/SCT Survivors NCT00579917 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors NCT00100347 | PRAECIS Pharmaceuticals Inc. | Phase 1 |
| Completed | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lym NCT00201877 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem- NCT00596154 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma NCT00151281 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach NCT00250718 | New Mexico Cancer Research Alliance | Phase 2 |
| Completed | A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma NCT00201669 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma NCT00285428 | Gilead Sciences | Phase 1 / Phase 2 |
| Recruiting | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies NCT00131014 | Dana-Farber Cancer Institute | — |
| Unknown | Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00090727 | Novacea | Phase 1 |
| Completed | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma NCT00220285 | Bayer | Phase 2 |
| Completed | Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma NCT00251394 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma NCT00384553 | University of Magdeburg | Phase 1 / Phase 2 |
| Completed | Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapse NCT00147953 | University of Cologne | Phase 2 |
| Completed | Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00184080 | University of Southern California | Phase 2 |
| Completed | Prevention of CHOP-induced Chronic Cardiotoxicity NCT00162955 | Osaka City University | Phase 4 |
| Completed | SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma NCT00076349 | Cephalon | Phase 2 |
| Unknown | A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma NCT00078598 | Corixa Corporation | Phase 3 |
| Completed | Allo-hNHL (FluBuCy) NCT00785330 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Phase 2 |
| Completed | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00323934 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas NCT00323323 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Unknown | Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients NCT00081783 | Xcyte Therapies | Phase 2 |